ProQR Therapeutics N.V.
ProQR Therapeutics N.V.
Your view on PRQR
Overview
What the company does, where it operates, and who runs it.
About ProQR Therapeutics N.V.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daniel Anton de Boer
- Headquarters
- Zernikedreef 9, Leiden, NL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daniel Anton de Boer
- Headquarters
- Zernikedreef 9, Leiden, NL
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
The company also engages in the developing of Axiomer RNA base-editing platform technology.
It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ProQR Therapeutics N.V., and the rating behind it. PRQR last traded at $1.86; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ProQR Therapeutics N.V.. Starting points for ProQR Therapeutics N.V.: EPS -$0.39, beta 0.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ProQR Therapeutics N.V.. ProQR Therapeutics N.V. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ProQR Therapeutics N.V.. Trailing twelve-month EPS for ProQR Therapeutics N.V. stands at -$0.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ProQR Therapeutics N.V.. ProQR Therapeutics N.V. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ProQR Therapeutics N.V. valued side by side against its closest peers. ProQR Therapeutics N.V. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ProQR Therapeutics N.V., and how their positions are changing. At a $195.9M market value, institutional positions materially move ProQR Therapeutics N.V.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ProQR Therapeutics N.V. executives and directors. Shares of ProQR Therapeutics N.V. have traded between $1.07 and $3.97 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ProQR Therapeutics N.V.. ProQR Therapeutics N.V. is a $195.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ProQR Therapeutics N.V.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ProQR Therapeutics N.V.. Coverage tracks ProQR Therapeutics N.V. within Biotechnology (Healthcare). Press releases and market coverage, newest first.